REVERSAL OF HYPER-PARATHYROIDISM IN RESPONSE TO DIETARY PHOSPHORUS RESTRICTION IN THE UREMIC DOG

被引:52
作者
KAPLAN, MA [1 ]
CANTERBURY, JM [1 ]
BOURGOIGNIE, JJ [1 ]
VELIZ, G [1 ]
GAVELLAS, G [1 ]
REISS, E [1 ]
BRICKER, NS [1 ]
机构
[1] UNIV MIAMI,SCH MED,DEPT MED,DIV ENDOCRINOL,MIAMI,FL 33152
关键词
D O I
10.1038/ki.1979.6
中图分类号
R5 [内科学]; R69 [泌尿科学(泌尿生殖系疾病)];
学科分类号
1002 ; 100201 ;
摘要
The role of phosphorus in the genesis of uremic hyperparathyroidism is well established. Prophylactic reduction of dietary phosphorus intake (PRS-P) in exact proportion to GFR reduction prevents renal hyperparathyroidism, but its effects on established hyperparathyroidism, serum calcium and phosphate concentration, and phosphorus balance are not known. Seven chronically uremic dogs (2 to 5 months) were housed in metabolic cages and maintained on a controlled phosphorus intake of 1,200 mg/day. After a control period of 10 days, the dogs were subjected to PRS-P. Control GFR averaged 16 ± 4 ml/min; serum phosphate concentration (SP), 4.3 ± 0.2 mg/dl; serum ionized calcium concentration (SICa), 4.67 ± 0.29 mg/dl; parathyroid hormone level (PTH), 610 ± 91 μl · Eq/ml; and 24-hr urine phosphate excretion (U(PO4)V), 845 ± 84 mg. During PRS-P, no change in GFR or SP occurred (17 ml/min and 4.3 mg/dl, respectively). S(ICa) increased significantly by day 2 and plateaued by day 4 at 5.13 ± 0.20 mg/dl. PTH fell progressively over the 16 days of PRS-P to 170 ± 49 μl/Eq/ml. U(PO4)V fell on day 1 of PRS-P and plateaued by day 2. Stool phosphorus excretion averaged 43% of intake. Total phosphorus excretion (urine plus stool) did not differ significantly from measured intake. Tubular maximum phosphate reabsorption/GFR averaged 2.7 ± 0.4 mg/100 ml before PRS-P and increased significantly to 4.9 ± 0.2 mg/100 ml after 18 days of PRS-P. In summary, dietary therapy with PRS-P appears to be an effective method, not only for preventing uremic hyperparathyroidism, but for reversing established uremic hyperparathyroidism. In view of the growing evidence that PTH may be a major 'uremic toxin', PRS-P could represent an important element in the future therapy of chronic renal failure.
引用
收藏
页码:43 / 48
页数:6
相关论文
共 42 条
  • [1] CALCIUM-METABOLISM OF BRAIN IN ACUTE RENAL-FAILURE - EFFECTS OF UREMIA, HEMODIALYSIS, AND PARATHYROID-HORMONE
    ARIEFF, AI
    MASSRY, SG
    [J]. JOURNAL OF CLINICAL INVESTIGATION, 1974, 53 (02) : 387 - 392
  • [2] BANK N, 1978, J CLIN INVEST, V60, P884
  • [3] BERKOW JW, 1968, AM J OPHTHALMOL, V66, P814
  • [4] BERNSTEIN DS, 1971, ISRAEL J MED SCI, V7, P513
  • [5] BETTER OS, 1976, ABST AM SOC NEPHR, V9, P1
  • [6] BRICKER NS, 1972, NEW ENGL J MED, V286, P1093
  • [7] COBURN JW, 1977, CALCIUM METABOLISM R, P77
  • [8] DAVID DS, 1977, CALCIUM METABOLISM R, P1
  • [9] IMPAIRED PARATHYROID-HORMONE METABOLISM IN PATIENTS WITH CHRONIC RENAL-FAILURE
    FREITAG, J
    MARTIN, KJ
    HRUSKA, KA
    ANDERSON, C
    CONRADES, M
    LADENSON, J
    KLAHR, S
    SLATOPOLSKY, E
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 1978, 298 (01) : 29 - 32
  • [10] PHOSPHORUS EXCRETION IN RENAL FAILURE
    GOLDMAN, R
    BASSETT, SH
    DUNCAN, GB
    [J]. JOURNAL OF CLINICAL INVESTIGATION, 1954, 33 (12) : 1623 - 1628